UniProt P21675
Transcription initiation factor TFIID subunit 1 (P21675)
Transcription initiation factor TFIID subunit 1 (UniProt P21675), EC 2.3.1.48, 2.7.11.1: 95 experimental structures on GenesisL1, 25 ligands bound, 68 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P21675
- Protein
- Transcription initiation factor TFIID subunit 1
- EC
- 2.3.1.48, 2.7.11.1
- Experimental structures
- 95
- Predicted models
- 0
- Ligands
- 25
- Pockets
- 68 · 25 records with a druggable one
Structures
95 records of P21675 in the MolNFT archive: 95 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1EQF | Crystal structure of the double bromodomain module from human TAFII250 | x-ray diffraction | A | — | — |
| 1EQF | Crystal structure of the double bromodomain module from human TAFII250 | x-ray diffraction | A | — | — |
| 3AAD | Structure of the histone chaperone CIA/ASF1-double bromodomain complex linking histone… | x-ray diffraction | A | — | — |
| 3AAD | Structure of the histone chaperone CIA/ASF1-double bromodomain complex linking histone… | x-ray diffraction | A | — | — |
| 3UV4 | Crystal Structure of the second bromodomain of human Transcription initiation factor TFIID subunit… | x-ray diffraction | A, B | — | — |
| 3UV4 | Crystal structure of the second bromodomain of human transcription initiation factor tfiid subunit… | x-ray diffraction | A, B | — | — |
| 3UV5 | Crystal Structure of the tandem bromodomains of human Transcription initiation factor TFIID subunit… | x-ray diffraction | A | — | — |
| 3UV5 | Crystal structure of the tandem bromodomains of human transcription initiation factor tfiid subunit… | x-ray diffraction | A | — | — |
| 4RGW | Crystal Structure of a TAF1-TAF7 Complex in Human Transcription Factor IID | x-ray diffraction | A | — | — |
| 4RGW | Crystal structure of a TAF1-TAF7 complex in human transcription factor iid | x-ray diffraction | A | — | — |
| 4YYM | Crystal structure of TAF1 BD2 Bromodomain bound to a butyryllysine peptide | x-ray diffraction | A, B | — | — |
| 4YYM | Crystal structure of TAF1 BD2 bromodomain bound to a butyryllysine peptide | x-ray diffraction | A, B | — | — |
| 4YYN | Crystal structure of TAF1 BD2 Bromodomain bound to a crotonyllysine peptide | x-ray diffraction | A, B | — | — |
| 4YYN | Crystal structure of TAF1 BD2 bromodomain bound to a crotonyllysine peptide | x-ray diffraction | A, B | — | — |
| 5FUR | Structure of human TFIID-IIA bound to core promoter DNA | electron microscopy | G | — | 7 (best 0.78) |
| 5FUR | Structure of human tfiid-iia bound to core promoter DNA | electron microscopy | G | — | — |
| 5I1Q | Second bromodomain of TAF1 bound to a pyrrolopyridone compound | x-ray diffraction | A | 67C | 1 (best 0.54) |
| 5I1Q | Second bromodomain of TAF1 bound to a pyrrolopyridone compound | x-ray diffraction | A | — | — |
| 5I29 | TAF1(2) bound to a pyrrolopyridone compound | x-ray diffraction | A | 67B, CA | 1 (best 0.48) |
| 5I29 | TAF1(2) bound to a pyrrolopyridone compound | x-ray diffraction | A | — | — |
| 5MG2 | Crystal structure of the second bromodomain of human TAF1 in complex with BAY-299 chemical probe | x-ray diffraction | A | 7M8 | 1 (best 0.50) |
| 5MG2 | Crystal structure of the second bromodomain of human TAF1 in complex with bay-299 chemical probe | x-ray diffraction | A | 7M8 | — |
| 6BQD | TAF1-BD2 bromodomain in complex with (E)-3-(6-(but-2-en-1-yl)-7-oxo-6… | x-ray diffraction | A, B | 69G | — |
| 6FIC | Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem | x-ray diffraction | T | DKH | 2 (best 0.50) |
| 6FIC | Bivalent inhibitor UNC4512 bound to the TAF1 bromodomain tandem | x-ray diffraction | T | DKH | — |
| 6MZD | Human TFIID Lobe A canonical | electron microscopy | A | — | 1 (best 0.68) |
| 6MZD | Human tfiid lobe a canonical | electron microscopy | A | — | — |
| 6MZL | Human TFIID canonical state | electron microscopy | A | — | 2 (best 0.76) |
| 6MZL | Human tfiid canonical state | electron microscopy | A | — | — |
| 6P38 | Crystal structure analysis of TAF1 bromodomain | x-ray diffraction | A | NQV | — |
| 6P39 | Crystal structure analysis of TAF1 bromodomain | x-ray diffraction | A | NQY | — |
| 6P3A | Crystal structure analysis of TAF1 bromodomain | x-ray diffraction | A, B | NQP | — |
| 7EDX | p53-bound TFIID-based core PIC on HDM2 promoter | electron microscopy | A | — | 1 (best 0.78) |
| 7EDX | P53-bound tfiid-based core pic on HDM2 promoter | electron microscopy | A | — | — |
| 7EG7 | TFIID-based core PIC on SCP promoter | electron microscopy | A | — | 2 (best 0.82) |
| 7EG7 | Tfiid-based core pic on scp promoter | electron microscopy | A | — | — |
| 7EG8 | Tfiid-based core pic on puma promoter | electron microscopy | A | — | — |
| 7EG9 | TFIID-based intermediate PIC on SCP promoter | electron microscopy | A | — | 1 (best 0.78) |
| 7EG9 | Tfiid-based intermediate pic on scp promoter | electron microscopy | A | — | — |
| 7EGA | TFIID-based intermediate PIC on PUMA promoter | electron microscopy | A | — | — |
| 7EGA | Tfiid-based intermediate pic on puma promoter | electron microscopy | A | — | — |
| 7EGB | TFIID-based holo PIC on SCP promoter | electron microscopy | A | — | 2 (best 0.81) |
| 7EGC | p53-bound TFIID-based holo PIC on HDM2 promoter | electron microscopy | A | — | — |
| 7EGD | Scp promoter-bound tfiid-tfiia in initial tbp-loading state | electron microscopy | A | — | — |
| 7EGE | Tfiid in canonical conformation | electron microscopy | A | — | — |
| 7EGH | Tfiid lobe C subcomplex | electron microscopy | A | — | — |
| 7EGI | TFIID in rearranged conformation | electron microscopy | A | — | 4 (best 0.79) |
| 7EGI | Tfiid in rearranged conformation | electron microscopy | A | — | — |
| 7EGJ | Scp promoter-bound tfiid-tfiia in post tbp-loading state | electron microscopy | A | — | — |
| 7ENA | TFIID-based PIC-Mediator holo-complex in pre-assembled state (pre-hPIC-MED) | electron microscopy | DA | — | — |
| 7ENC | TFIID-based PIC-Mediator holo-complex in fully-assembled state (hPIC-MED) | electron microscopy | DA | — | — |
| 7JJG | Crystal structure of the second bromodomain (BD2) of human TAF1 bound to atr kinase inhibitor AZ20 | x-ray diffraction | A | VCD | — |
| 7JJH | Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1 | x-ray diffraction | A | — | 2 (best 0.51) |
| 7JJH | Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1 | x-ray diffraction | A | — | — |
| 7JSP | Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor… | x-ray diffraction | A | VJM, SO4 | 1 (best 0.49) |
| 7JSP | Crystal structure of the second bromodomain (BD2) of human TAF1 bound to atr kinase inhibitor… | x-ray diffraction | A | VJM, SO4 | — |
| 7JTC | Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322 | x-ray diffraction | A | VK1 | 1 (best 0.50) |
| 7JTC | Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322 | x-ray diffraction | A | VK1 | — |
| 7K03 | Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ATR kinase… | x-ray diffraction | A | VJM | 3 (best 0.65) |
| 7K03 | Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to atr kinase… | x-ray diffraction | A | VJM | — |
35 records more on the page itself.
Ligands
- SO4 · Sulfate ion · in 6 records
- VJM · 4-(4-{1-[(R)-amino(hydroxy)methyl-lambda~4~-sulfanyl]cyclopropyl}-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridine · in 4 records
- VCD · 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole · in 3 records
- 06M · 6-(but-3-en-1-yl)-4-[6-{1-[(R)-S-methanesulfonimidoyl]cyclopropyl}-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one · in 2 records
- 7M8 · 6-(3-oxidanylpropyl)-2-(1,3,6-trimethyl-2-oxidanylidene-benzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione · in 2 records
- BMF · Bromosporine · in 2 records
- DKH · 3-azanyl-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[3-azanyl-1-[[2-[[3-methyl-6-[4-methyl-3-(methylsulfonyl-$L^{2}-azanyl)cyclohexa-1,3,5-trien-1-yl]-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]-$L^{2}-azanyl]-2-oxidanylidene-ethyl]amino]-1-oxidanylidene-propan-2-yl]amino]-2-oxidanylidene-ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethox y]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]eth oxy]ethoxy]propanoylamino]-~{N}-[3-[[3-methyl-6-[4-methyl-3-(methylsulfonylamino)phenyl]-[1, · in 2 records
- E9F · 4-(6-{1-[(R)-S-methanesulfonimidoyl]cyclopropyl}-2-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine · in 2 records
- EIO · (3R)-4-[6-{1-[diamino(hydroxy)-lambda~4~-sulfanyl]cyclopropyl}-2-(methylsulfanyl)pyrimidin-4-yl]-3-methylmorpholine · in 2 records
- G9V · 6-(but-3-en-1-yl)-4-[1-methyl-6-(morpholine-4-carbonyl)-1H-benzimidazol-4-yl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one · in 2 records
- VK1 · 1-{6-[(3R)-3-methylmorpholin-4-yl]-2-(methylsulfanyl) pyrimidin-4-yl}cyclopropane-1-sulfonimidoamide · in 2 records
- XWV · 5-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}isoquinoline · in 2 records
- XXV · 1-{6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl}cyclopropane-1-sulfonamide · in 2 records
- 5LV · 8-[[1-(3-azanylpropyl)piperidin-4-yl]amino]-5-[5-(hydroxymethyl)pyridin-3-yl]-3-methyl-1~{H}-1,7-naphthyridin-2-one · in 1 record
- 67B · N,N-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide · in 1 record
- 67C · 3-[6-(but-3-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl]-N,N-dimethylbenzamide · in 1 record
- 69G · 3-{6-[(2E)-but-2-en-1-yl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-N,N-dimethylbenzamide · in 1 record
- CA · Calcium ion · in 1 record
- NQP · 4-{[(3R)-1-(but-3-en-1-yl)-3-methyl-4-(oxan-4-yl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl) benzamide · in 1 record
- NQV · 4-{[(3R)-4-cyclopentyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl]amino}-N-(1-methylpiperidin-4-yl)-3-[(propan-2-yl)oxy]benzamide · in 1 record
- NQY · 3-methoxy-4-{[(6ar)-5-methyl-6-oxo-6,6A,7,8,9,10-hexahydro-5H-dipyrido[1,2-A:3',2'-e]pyrazin-2-yl]amino}-N-(1-methylpiperidin-4-yl)benzamide · in 1 record
- R78 · 4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide · in 1 record
- VQS · N-(4-{4-[1-(cyclopropylsulfonyl)cyclopropyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl}phenyl)-N'-(2-hydroxyethyl)thiourea · in 1 record
- XWY · (3R)-3-methyl-4-{6-[1-(S-methylsulfonimidoyl) cyclopropyl]-2-(naphthalen-1-yl)pyrimidin-4-yl}morpholine · in 1 record
- XXS · 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-indazole · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.